Prev Close | 193.09 |
Open | 195.33 |
Day Low/High | 194.50 / 199.78 |
52 Wk Low/High | 187.16 / 468.55 |
Volume | 972.07K |
Prev Close | 193.09 |
Open | 195.33 |
Day Low/High | 194.50 / 199.78 |
52 Wk Low/High | 187.16 / 468.55 |
Volume | 972.07K |
Exchange | NASDAQ |
Shares Outstanding | 146.45B |
Market Cap | 28.66B |
P/E Ratio | 8.89 |
Div & Yield | N.A. (N.A) |
It's not the Fed chief's place.
And it's not the favorable macroeconomic climate.
Biogen miss no reason to abandon big 4 of Big Pharma.
Apple provides a fantastic platform, but there are other places to profit in the connected device arena such as NXP Semiconductors.
For Friday, April 24 we watch for quarterly financial results from drug maker Biogen (BIIB), copy machine company Xerox (XRX), and American Airlines (AAL).
Telecom, utility and energy names led the way higher Thursday.
Gilead's Relative Strength Index slope is very strong.
Gilead's Relative Strength Index slope is very strong.
Even the second-tier biotechs are taking off.
The market is neither making progress nor shifting into a downtrend.
After share price falls from March high, it may be ready to bounce.
An answer to those asking me what's worth buying.
But wait for a pullback before getting in.
Good buys kept getting overlooked.
A strategy to immunize biotech investors from regret.
Its Alzheimer's treatment impressed, but dosing questions remain.
If it doesn't heat up, traders may start selling more aggressively.
Here are healthcare stocks of all shares and sizes with strong charts.
Own them, or take something off the table?
It was encouraging to see the market broaden out like this.
I really like the stocks. But I also like making money on stocks.
The market opened on a very strong note and Biogen Idec is up big after announcing study of its experimental drug for Alzheimer's disease had exceeded expectations. The whole biotech sector is having another strong day after yesterday's huge outper...
As always, I am happy to be standing in for Doug Kass today on the Daily Diary (this Friday from sunny Miami). It looks like it will be an up open to talk about based on early market futures. The euro is heading towards its best week in 18 months, e...
Market backtracks on skepticism over biotechs.
Biotechs are still bubbly in 'stock pickers' market.
A Fed-related dip may be your only hope to get in lower.
It shouldn't be possible, but it never seems too late to get in.
There's still plenty of action out there.
Sector could regain its leadership role.